Overview

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Status:
Completed

Trial end date:
2018-10-26

Target enrollment:

Participant gender:

Summary

This is a Phase 2 open-label study to evaluate the efficacy and safety of ibrutinib in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory multiple myeloma.

Phase:

Phase 2

Details

Lead Sponsor:

Pharmacyclics LLC.
Pharmacyclics Switzerland GmbH

Collaborator:

Janssen Research & Development, LLC

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate